Risperidone, haloperidol and clozapine in the South Carolina medicaid program: A comparative analysis of utilisation and expenditure

Disease Management and Health Outcomes

Volumn 9, Issue 4, 2001, Pages 203-213

  Shermock, K M ^a   Sadik, M K ^b   Kozma, C M ^c   Sesti, A M ^d   Reeder, C E ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Strategic Outcomes Services Inc   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG USE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL FEE; MENTAL HEALTH CARE; PRESCRIPTION; SCHIZOPHRENIA; UNITED STATES;

EID: 0035052681     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200109040-00003     Document Type: Article

References (23)

1. Prediction of outcome in first-episode schizophrenia
2. Management of schizophrenia
3. The costs of schizophrenia
4. Schizophrenia
5. Schizophrenia
6. Chronic schizophrenia: Options for pharmacologic management
7. Atypical antipsychotic drugs as first-line treatment of schizophrenia: A rationale and hypothesis
8. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
9. Neuroleptic-induced extrapyramidal symptoms and the role of combined serotonin/dopamine antagonism
10. A Canadian multicenter placebo-controlled study of fixed dose of risperidone and haloperidol in the treatment of chronic schizophrenic patients
11. Clozapine for the treatment resistant schizophrenic: A double blind comparison with chlorpromazine
12. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study
13. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
14. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases
15. Impact of risperidone on the use of mental health care resources
16. Economic outcomes of antipsychotic agents in a Medicaid population: Traditional agents vs risperidone
17. Schizophrenia: A follow-up study of results of treatment: II: Hospital stay over two to five years
18. A randomized controlled trial of prophylactic neuroleptic treatment
19. Duration of psychosis and outcome in first episode schizophrenia
20. Neuroleptics and the natural course of schizophrenia